Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

The Lymphoma Academic Research Organisation: Clinical Trials & FDA Approval Profile

The Lymphoma Academic Research Organisation (Global / Institutional) sponsors 20 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 14 active protocols (5 recruiting now), 6 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)0.0%
Median Closed Enrollment vs National (145 pts)71 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for The Lymphoma Academic Research Organisation
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)20
Active Pipeline (Recruiting Now)14 (5)
Completed vs Stopped Early6 / 0 (0.0%)
Median Closed Actual Enrollment71 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With The Lymphoma Academic Research Organisation
Hospital Research SiteLocationShared Protocols
Centre Henri BecquerelRouen12

Explore interactive annual charts and M&A subsidiary rollups in the The Lymphoma Academic Research Organisation Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI